SCHEMBL21496522

SCHEMBL21496522

C[C@H](C(=O)Nc1cnc(Cl)c(Cl)c1)C12CC(NC(=O)c3ccc(Cl)c(Cl)c3)(C1)C2

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 13/20 0.63
▸ KCNQ3 O43525 1/20 0.43
▸ KCNQ2 O43526 1/20 0.43
▸ KCNE1 P15382 1/20 0.43
▸ KCNQ1 P51787 1/20 0.43
▸ MAOB P27338 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ GAA P10253 1/20 0.40
▸ HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21496524 1.00 IDO1 (0.63) IDO1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL30055202 1.00 IDO1 (0.63) IDO1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL21496538 0.91 IDO1 (0.68) IDO1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL21496536 0.91 IDO1 (0.68) IDO1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL30055400 0.90 IDO1 (0.66) IDO1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL21496437 0.90 IDO1 (0.66) IDO1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL21496438 0.90 IDO1 (0.66) IDO1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL24117916 0.88 IDO1 (0.77) IDO1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL30055204 0.88 IDO1 (0.77) IDO1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL21496553 0.87 IDO1 (0.68) IDO1KCNQ3KCNQ2KCNE1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3781142-A1 NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS Merck Sharp&Dohme Corp. (US) 2021-02-24 — — EP claimed
WO-2019204180-A1 NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2019-10-24 — — WO claimed
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors MERCK SHARP & DOHME CORP. (US) 2021-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors IDO1, IDO2, TPH1 IDO1 1/4885KCNQ3 4341/4885KCNQ2 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback